Click here - to use the wp menu builder

BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071

October 6, 2020

SAN DIEGO & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $BGNE #BGNE–BeiGene will hold an exclusive license to the global clinical development and commercialization of BioAtla’s investigational CAB CTLA-4 antibody.

Source

BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071

Recent Articles

Moderna Announces Supply Agreement to Provide 13 Million Doses of COVID-19 Vaccine Moderna to the Philippines

Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis

EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients

U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy

Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir